STOCK TITAN

BeOne Medicines (NASDAQ: ONC) ex-director lines up $788K ADS sale

(Neutral)
(Neutral)
Form Type
144

Rhea-AI Filing Summary

BeOne Medicines Ltd. (ONC) has a notice of proposed sale under Rule 144 filed for securities beneficially owned by former director Corazon D. Sanders. The notice covers the planned sale of 2,075 ADS of BeOne Medicines Ltd., with an aggregate market value of $788,500.00, to be sold through Morgan Stanley Smith Barney LLC Executive Financial Services on or after 08/25/2026 on the NASDAQ market. The ADS were acquired by exercise of options under a registered plan for cash. In the preceding three months, Sanders sold 945 shares of common stock of BeOne Medicines Ltd. on 06/15/2026 for aggregate proceeds of $250,893.81.

Positive

  • None.

Negative

  • None.
ADS to be sold 2,075 ADS Planned sale under Rule 144 for BeOne Medicines Ltd.
Aggregate market value of ADS $788,500.00 Value associated with the 2,075 ADS to be sold
Planned sale date for ADS 08/25/2026 Date associated with the Rule 144 ADS sale
Common shares sold in past 3 months 945 shares Common stock of BeOne Medicines Ltd. sold on 06/15/2026
Proceeds from prior common share sale $250,893.81 Aggregate proceeds from sale of 945 common shares on 06/15/2026
Rule 144 regulatory
"See the definition of "person" in paragraph (a) of Rule 144."
Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.
ADS financial
"ADS | Morgan Stanley Smith Barney LLC Executive Financial Services"
Ads are paid promotional messages a company places across media — online, on TV, in print, or on social platforms — to attract customers, explain products, or shape public perception. For investors, ads matter because they drive sales growth, affect how much a company must spend to win customers, and influence brand strength and long-term value. Ads can also create regulatory or reputational risk if claims are misleading, which can affect profits and stock price.
Exercise of Options Under a Registered Plan financial
"Exercise of Options Under a Registered Plan | Issuer"

FAQ

What securities are being sold under Rule 144 for BeOne Medicines Ltd. (ONC)?

The notice covers the proposed sale of 2,075 American Depositary Shares (ADS) of BeOne Medicines Ltd., with an aggregate market value of $788,500.00, to be sold through Morgan Stanley Smith Barney LLC Executive Financial Services.

Who is selling BeOne Medicines Ltd. (ONC) shares under this Form 144?

The securities are to be sold for the account of Corazon D. Sanders, identified as a Former Director of BeOne Medicines Ltd.

How and when were the BeOne Medicines Ltd. (ONC) ADS to be sold acquired?

The 2,075 ADS to be sold on or after 08/25/2026 were acquired by exercise of options under a registered plan, with the form indicating the acquisition method as Cash.

On which market will the BeOne Medicines Ltd. (ONC) ADS be sold?

The notice states that the ADS of BeOne Medicines Ltd. are to be sold on the NASDAQ market.

What BeOne Medicines Ltd. (ONC) shares has Corazon D. Sanders sold in the past 3 months?

In the preceding three months, 945 shares of common stock of BeOne Medicines Ltd. were sold on 06/15/2026 for aggregate proceeds of $250,893.81.

Which broker is handling the BeOne Medicines Ltd. (ONC) Rule 144 sale?

The proposed sale of 2,075 ADS is to be handled by Morgan Stanley Smith Barney LLC Executive Financial Services, located at 1 New York Plaza, New York, NY.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature